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Abstract
Background: Extra-label use of tulathromycin in lactating goats is common and may cause violative residues in
milk. The objective of this study was to develop a nonlinear mixed-effects pharmacokinetic (NLME-PK) model to
estimate tulathromycin depletion in plasma and milk of lactating goats. Eight lactating goats received two
subcutaneous injections of 2.5 mg/kg tulathromycin 7 days apart; blood and milk samples were analyzed for
concentrations of tulathromycin and the common fragment of tulathromycin (i.e., the marker residue CP-60,300),
respectively, using liquid chromatography mass spectrometry. Based on these new data and related literature data,
a NLME-PK compartmental model with first-order absorption and elimination was used to model plasma
concentrations and cumulative excreted amount in milk. Monte Carlo simulations with 100 replicates were
performed to predict the time when the upper limit of the 95% confidence interval of milk concentrations was
below the tolerance.
Results: All animals were healthy throughout the study with normal appetite and milk production levels, and with
mild-moderate injection-site reactions that diminished by the end of the study. The measured data showed that milk
concentrations of the marker residue of tulathromycin were below the limit of detection (LOD = 1.8 ng/ml) 39 days
after the second injection. A 2-compartment model with milk as an excretory compartment best described
tulathromycin plasma and CP-60,300 milk pharmacokinetic data. The model-predicted data correlated with the
measured data very well. The NLME-PK model estimated that tulathromycin plasma concentrations were below
LOD (1.2 ng/ml) 43 days after a single injection, and 62 days after the second injection with a 95% confidence.
These estimated times are much longer than the current meat withdrawal time recommendation of 18 days for
tulathromycin in non-lactating cattle.
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Conclusions: The results suggest that twice subcutaneous injections of 2.5 mg/kg tulathromycin are a clinically
safe extra-label alternative approach for treating pulmonary infections in lactating goats, but a prolonged withdrawal
time of at least 39 days after the second injection should be considered to prevent violative residues in milk and any
dairy goat being used for meat should have an extended meat withdrawal time.
Keywords: Tulathromycin, Withdrawal time, Goat, Food safety, Nonlinear mixed-effects (NLME) pharmacokinetic
modeling
Background
Drug residues in edible tissues of food-producing animals
are a global food safety concern [1, 2]. Tulathromycin is a
widely used long-acting triamilide antibiotic labeled for
treating respiratory diseases in cattle and swine, and also
commonly used in goats in an extra-label manner because
it is highly effective against caprine respiratory pathogens
[3] and is clinically safe when administered to neonatal
dairy and meat goats at 1X, 3X, and 5X the cattle label
dose [4]. In the US and Europe, there is no established
milk tolerance (equivalent to maximum residue level in
Europe) for tulathromycin in goats, thus any detectable
residues are considered violative. Therefore, it is important
to determine the appropriate withdrawal time needed for
tulathromycin concentrations in edible tissues/milk to fall
below legally established safe levels (in this case the analyt-
ical detection limit) to ensure food safety.
Physiologically based pharmacokinetic (PBPK) and non-
linear mixed-effects pharmacokinetic (NLME-PK) models
are helpful tools in the establishment of withdrawal time
guidelines for veterinary drugs [5–7]. Currently, there are
pharmacokinetic data for tulathromycin in the plasma and
tissues of juvenile and market-age goats after single or
multiple intravenous (IV), intramuscular (IM), or subcuta-
neous (SC) injections [3, 8, 9]. A PBPK model has been
developed to help estimate meat withdrawal times for
tulathromycin in juvenile and market-age goats [10]. For
lactating goats, however, there are only pharmacokinetic
data in the plasma and milk after single IV, IM, or SC in-
jection [11, 12], but not after repeated administrations.
PBPK or NLME-PK models for tulathromycin in lactating
goats are not available, either.
Repeated administrations are a common and important
dosing strategy in order to maintain therapeutically effect-
ive drug concentrations in the plasma and tissues for longer
periods of time. A recent study suggested that in order to
maintain lung concentrations of tulathromycin higher than
minimal inhibitory concentrations (MIC) for respiratory
pathogens (e.g., MIC = 2 μg/mL forM haemolytica), the SC
injection interval in goats should be every 7 days [9]. A
major concern of repeated administrations of veterinary
drugs in food-producing animals is the potential accumula-
tion of drugs in the body, resulting in prolonged withdrawal
times. The objective of this study was to determine the
pharmacokinetic characteristics of tulathromycin in lactat-
ing goats after two administrations, and to develop a
NLME-PK model to estimate tulathromycin depletion in
plasma and milk samples after single and two SC injec-
tions in lactating goats.
Methods
Pharmacokinetic study design
Eight healthy adult (1–7 years old) lactating goats with a
mean body weight of 88 kg (range: 73–109 kg) and a
mean milk production of 10.8 lbs/day (range: 7–14 lbs/
day) in their first to sixth lactation were used in the
present study. Breeds included Saanen (n = 4), LaMancha
(n = 3), and Toggenburg (n = 1) goats. Does were housed
individually in the Goat Teaching and Research Facility at
University of California, Davis, CA. All does met the
inclusion criteria, including passing a normal physical
examination, lactating for at least 45 days, and no anti-
biotic treatment in the last 2 months. Prior to tulathro-
mycin injection, composite milk samples representing
one entire milking period (instead of foremilk or strip-
pings) were collected using a Dairy Herd Improvement
Association-approved milk metering device. Goats were
then injected with 2.5 mg/kg tulathromycin (Draxxin®;
Zoetis Inc., New York, NY) subcutaneously in the thoracic
region caudal to elbow (first injection at left elbow and
second injection at right elbow) twice on Day 0 and Day 7
(7-day interval), immediately after the evening milking.
Doses were calculated based on body weights collected
the day before injection. Health status and injection-site
reactions were monitored daily for 64 days after the first
injection.
Individual doe milk samples were collected twice daily
during regular milking times (morning milking at 6:30 a.m.
and evening milking at 5:30 p.m.) for days 1–21 after the
first injection, then once every 48 h at the morning milking
for days 22–36 after the first injection, and every 72 h
at the morning milking for days 37–64 after the first in-
jection. Does were machine-milked; milk was collected
using a commercial milk meter/sampler (Waikato Milking
Systems, Hamilton, New Zealand) and the milk weights
were recorded. Milk samples (~10–13 mL/sample) were
transferred into 15 mL conical tubes, frozen at −20 °C
within 30 min of collection, and then stored at −80 °C
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until analysis. Blood was collected twice daily, following
each milking, during the first 7 days after the second injec-
tion via jugular venipuncture into heparinized blood tubes.
Tubes were placed on ice, centrifuged at 1200 g for 5 min
at 4 °C, and plasma samples were manually harvested and
transferred to storage tubes, which were then immediately
frozen at −20 °C and then stored at a −80 °C freezer until
analysis. All animal procedures were approved in advance
by the Animal Care and Use Committee of the University
of California, Davis, CA.
Tulathromycin analysis
Plasma tulathromycin concentrations were determined
using the liquid chromatography mass spectrometry
(LC-MS) method described in Galer et al. [13], while
milk samples were analyzed for the concentrations of
CP-60,300, a common fragment of tulathromycin and its
metabolites, with an LC-MS method described by Boner
et al. [14] because CP-60,300 is the marker residue of
tulathromycin and all current US FDA guidelines on
tulathromycin tolerances in the milk or target tissues are
based on CP-60,300. Briefly, the LC was an Acquity®
UPLC from Waters (Milford, MA) and the MS was a
Thermo TSQ Quantum Discovery Max (Thermo Fisher
Scientific, Waltham, MA) with a heated electrospray
ionization source. Sample injections were prepared on an
Ace C8, 2.1 × 50 mm, 3 μm column (MacMod, Chadds
Ford, PA). Positive ions were monitored in the selected re-
action monitoring (SRM) mode for CP-60,300 and an in-
ternal standard (a structurally similar compound provided
by Pfizer [New York City, NY]) with transitions from
577.2 to 420.2 and from 591.3 to 434.2, respectively. For
tulathromycin, the positive ions were monitored in the
SRM mode with the doubly charged precursor to product
ion pair of 404.1 to 578.0. The limit of detection (LOD)
was 1.8 and 1.2 ng/mL for milk and plasma, respectively,
and the limit of quantification (LOQ) was 5.0 ng/mL for
milk and 4.0 ng/mL for plasma. The average inter-assay
variation was measured by relative standard deviation
(%RSD) and was 6.6% for milk and 11.3% for plasma. The
milk quality control concentrations were 6, 60, and
600 ng/ml, and the plasma quality control concentrations
were 15, 225, and 450 ng/ml. The recovery was 100% for
milk and 96.7% for plasma.
Pharmacokinetic analysis
Milk and plasma tulathromycin concentration-time data
were analyzed for each individual animal using a non-
compartmental approach (Phoenix WinNonlin®, version
6.4, Certara Inc., Cary, NC). Furthermore, tulathromycin
plasma concentration and cumulative drug amount ex-
creted in milk data were analyzed using the NLME-PK
modeling approach in Phoenix NLME (version 1.3, Certara
Inc., Cary, NC). The extended least-squares, first-order
conditional estimation method (FOCE-ELS) with inter-
action was employed to fit the data to the model and
calculate the pharmacokinetic parameters. Typical popula-
tion pharmacokinetic parameter values, interindividual
variability (IIV), residue error, and 95% confidence
interval were calculated [15, 16]. Between-individual
and between-occasion variability was assessed with an
exponential model. Residual variability was tested using
the additive, proportional, and combined error models.
Compartment model selection was guided by goodness-
of-fit plots (e.g., observed vs. predicted plasma concentra-
tions and milk cumulative amounts, weighted residuals vs.
predicted concentrations/amounts, and weighted residuals
vs. time), the −2 log-likelihood (−2LL), Akaike information
criterion (AIC), as well as the Bayesian information criter-
ion (BIC). The model was selected on the basis of smaller
values of AIC, better precision of estimates, and superior
goodness-of-fit plots.
In order to determine whether the dosing regimen
(single vs. twice injections) has an effect on tulathromycin
depletion, plasma concentration and milk amount data of
tulathromycin after a single SC injection in lactating goats
(n = 8) from Grismer et al. [12] were included in the
NLME-PK analysis. Briefly, eight adult (2–5 years) lactat-
ing dairy goats (body weight range: 72.5-89.0 kg) in their
first to fourth lactation that met the inclusion criteria as
described above were used in this study. Goats were
injected with a single dose of 2.5 mg/kg tulathromycin
(Draxxin®; Zoetis Inc., New York, NY) subcutaneously in
the left thoracic region caudal to the elbow. Individual
milk samples were collected starting at 12 h after injection
twice daily during regular milking times (6 a.m. and
5 p.m.) from days 1–14, then once every 48 h (a.m. milk-
ing time) from days 14–28, and then every 72 h (a.m.
milking time) from days 28–45 post injection. Blood sam-
ples were collected twice daily after each milking during
the first 7 days after injection via jugular venipuncture into
heparinized tubes. In addition, due to lack of absorption
phase (<12 h) concentration data in the present study and
the study by Grismer et al. [12], raw data from another
study by Clothier et al. [3] where tulathromycin plasma
concentrations were measured as early as 1 min after
a single SC injection (2.5 mg/kg) in market age goats
(n = 10), was also incorporated into the NLME-PK
analysis. In brief, five daily mixed breed and five Boer
male (intact and castrated; 6-month-old) goats received
one SC injection of 2.5 mg/kg tulathromycin (Draxxin®;
Pfizer Animal Health, New York, NY). Blood samples
were collected from the jugular vein at 1, 2, 4, 6, 8, and
10 min, as well as at 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96,
120, 144, 168, 192, 216, 240, 264, 288, 312, 336, and 360 h
after injection. Plasma tulathromycin and milk CP-60,300
concentrations were analyzed using the same methods as
described above.
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Simultaneous modeling of plasma and milk data
The structural model for combined plasma and milk data
was built sequentially. Firstly, a 1-, 2-, or 3-compartments
model with first-order absorption and first-order elimin-
ation was fit to the plasma concentration data, and the best
structural model was selected. Next, a milk compartment
was added, and simultaneous modeling of plasma and milk
data was then performed. The final pharmacokinetic
structural model developed for tulathromycin plasma
concentrations and milk cumulative amount excreted is
shown in Fig. 1. Differential equations describing this
pharmacokinetic model are shown below:
dA1
dt
¼ Aa  Ka− Cl  Cð Þ− Cl2 C−C2ð Þ½ − CLmilk  Cð Þ
ð1Þ
dAa
dt
¼ −Aa  Ka ð2Þ
dA2
dt
¼ Cl2 C−C2ð Þ ð3Þ
C ¼ A1=V ð4Þ
C2 ¼ A2=V 2 ð5Þ
dAmilk
dt
¼ CLmilk  C ð6Þ
where A1 is the total amount in the central compartment,
Aa is the amount in the absorption compartment via SC
injection, A2 is the total amount in peripheral compart-
ment, Amilk is the cumulative amount excreted in the milk,
C is the concentration in the central compartment, C2 is
the concentration in the peripheral compartment. Def-
initions of pharmacokinetic parameters are provided
in Table 3.
Model evaluation
The performance and stability of the final pharmacoki-
netic model was evaluated with both graphical method by
visually comparing predicted vs. observed data, as well as
the bootstrap analysis. The bootstrap samples were col-
lected through random sampling by replacing the original
dataset to generate another dataset with the same sample
size as the original but with a different combination of
subjects. The bootstrap resampling analysis was repeated
100 times and conducted in Phoenix NLME. If the major-
ity of the parameter estimates fell into the 95% confidence
intervals (CIs) of the bootstrap values, the model was con-
sidered unbiased. However, if any parameter estimate was
out of the 95% CI, possible reasons were explored and
discussed.
Model simulations
The final model was used in Phoenix NLME to conduct
Monte Carlo simulations under dosing regimens of
2.5 mg/kg once or twice with 7-day interval via SC injec-
tion(s). For each dosing schedule, the Monte Carlo
simulation generated time-concentration (or amount)
profiles of tulathromycin in plasma and milk for 100
replicates. The simulated data were used to estimate the
times when the upper limits of the 95% confidence inter-
vals of simulated plasma and milk concentrations were
below the tolerances. Simulated milk concentrations
were calculated by dividing the simulated excreted
amounts in milk by the measured milk volumes pro-
duced over the period of time between samples. There
are no official tolerances for tulathromycin in lactating
goats in the US or Europe, so the limits of detection
(LODs) in plasma (1.2 ng/ml) and milk (1.8 ng/ml) were
used as the most conservative endpoint.
Results
General health and pharmacokinetic data
All goats were healthy throughout the study with normal
appetite and milk production levels. The body weight
did not change significantly before nor at the end of the
study. Four animals exhibited drug administration reac-
tions, including vocalization, extension/flexion of the
front limb, and/or looking back at the elbow. Similar to
what we observed in our previous single injection study
[12], injection-site reactions ranged from mild swelling
to multiple skin lesions. All swellings diminished from
their maximum size by the end of the study.
The plasma and milk concentration-time data collected
during the current study are shown in Fig. 2. The average
plasma and milk non-compartmental pharmacokinetic
Fig. 1 Schematic representation of the final pharmacokinetic model
for plasma tulathromycin concentrations and milk cumulative excreted
amounts of tulathromycin marker residue CP-60,300 in lactating goats.
A1 is the total amount in the central compartment (ng); Aa is the
amount in the absorption compartment via SC injection (ng); A2 is the
total amount in peripheral compartment (ng); Amilk is the cumulative
excreted amount in the milk (ng); Cl is central clearance (mL/h); Cl2 is
clearance between the central and the peripheral compartment
(mL/h); Clmilk is clearance from the central compartment to the
milk (mL/h); Ka is absorption rate constant after SC injection (1/h);
V is volume of distribution for the central compartment (mL); V2 is
volume of distribution for the peripheral compartment (mL)
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parameter values are shown in Table 1, while Table 2
shows the average plasma and milk concentration data.
The plasma pharmacokinetic profile of tulathromycin after
the second injection reported in this study were somewhat
different numerically from that observed in the previous
study using a different population of lactating goats (n = 8)
after a single injection [12]. However, the pharmacokinetic
parameter values between the first and the second injec-
tions could not be compared statistically because the data
were from two different studies using two different popu-
lations of animals. The milk concentration and pharmaco-
kinetic parameters were analyzed after both the first and
the second injections in the present study. The elimination
rate constant (λz) was lower and the elimination half-life
(T1/2λz) longer after the second compared to the first in-
jection; other parameters were not statistically different
(Table 1).
Structural NLME-PK model development
Results of model comparison and evaluation between
the 3-compartment and 2-compartment models based on
the data in lactating goats only are provided in Additional
file 1: Figure S1. In addition, comparisons of model evalu-
ation results of the initial 2-compartment model (without
the absorption phase data) and the final 2-compartment
model (with the absorption phase data from [3]) are
shown in Additional file 2: Figure S2. Overall, a 2-
compartment model with first-order absorption and
first-order elimination best characterized the plasma
concentration data. A total of 232 plasma concentrations
of tulathromycin in lactating goats and 300 plasma con-
centrations in market meat goats were simultaneously
modeled. The plasma pharmacokinetic model parameters
are provided in Table 3. The distribution of residual
variability was most adequately characterized with a
proportional error model. A total of 411 milk cumula-
tive excreted amounts were added to develop the milk
pharmacokinetic model.
Model evaluation
Goodness-of-fit plots from the final pharmacokinetic
model are presented in Fig. 3. The plots displayed an
excellent correlation between the model-predicted and
observed values. Figure 4 shows the comparisons of
time-concentration (or amount) profiles vs. the individual
predicted data in plasma and milk. The model adequately
captured the pharmacokinetic profiles of tulathromycin
and CP-60,300 in plasma and milk, respectively.
Fig. 2 Plots of tulathromycin concentration versus time in plasma (a) and CP-60,300 concentration versus time in milk (b)
Table 1 Noncompartmental pharmacokinetic parameters for tulathromycin in plasma and the marker residue CP-60,300 in milk of
lactating goats following two subcutaneous injections of 2.5 mg/kg tulathromycin at 7-day interval
Pharmacokinetic
parameters (units)
Plasma (injection 2 only) Milk (injection 1) Milk (injection 2)
mean SD mean SD mean SD p value#
Cmax (obs) (ng/mL) 155.211 39.501 1806.280 660.824 1457.238 282.876 0.191
Tmax (obs) (h) 16.828 8.880 15.016 5.240 17.930 9.017 0.574
λz (1/h) 0.013 0.002 0.017 0.006 0.005 0.001 <0.001
T1/2λz (h) 56.421 8.265 51.752 35.768 158.002 40.291 <0.001
AUClast (h*ng/mL) 8050.601 1532.931 61805.331 6351.608 68156.845 12472.633 0.220
AUCinf (h*ng/mL) 9120.588 1599.754 65147.987 7889.685 68978.306 12598.494 0.478
Cmax (obs): observed maximum plasma or milk concentration; Tmax (obs): time to observed maximum plasma or milk concentration after each injection;
λz: elimination rate constant; T1/2λz: elimination half-life; AUClast: area under the plasma or milk concentration vs. time curve to the last sampled value;
AUCinf: area under the plasma or milk concentration vs. time curve extrapolated to infinity
#p values of Student’s t test of the difference in the milk pharmacokinetic parameters between the first injection and the second injection
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Table 2 Average concentrations of tulathromycin in plasma and the marker residue CP-60,300 in milk after twice subcutaneous
injections of 2.5 mg/kg tulathromycin in lactating goats
Time Plasma SD Milk SD Time Plasma SD Milk SD
12 NA NA 1791.4 672.02 360 NA NA 64.3 20.39
24 NA NA 1167.0 264.23 372 NA NA 26.9 8.23
36 NA NA 763.7 226.64 384 NA NA 47.7 16.54
48 NA NA 364.8 109.83 396 NA NA 46.7 18.93
60 NA NA 281.1 103.50 408 NA NA 45.9 16.43
72 NA NA 140.3 30.71 420 NA NA 37.0 15.74
84 NA NA 154.1 45.25 432 NA NA 32.8 10.11
96 NA NA 107.1 23.03 444 NA NA 30.3 10.55
108 NA NA 131.4 39.94 456 NA NA 24.0 7.51
120 NA NA 90.6 23.20 468 NA NA 23.9 7.56
132 NA NA 56.7 15.54 480 NA NA 22.1 10.49
144 NA NA 59.2 14.50 492 NA NA 23.3 14.07
156 NA NA 50.2 9.61 504 NA NA 25.4 12.87
168 NA NA 41.0 11.11 540 NA NA 20.6 6.28
180 152.5 39.03 1392.8 363.32 588 NA NA 12.0 4.25
192 105.8 44.82 1096.9 151.09 636 NA NA 8.3 3.55
204 75.1 36.48 789.3 292.69 684 NA NA 8.0 4.91
216 61.9 20.64 424.9 168.10 732 NA NA 6.5 1.42
228 39.3 19.24 230.1 101.49 780 NA NA 6.0 2.21
240 46.2 18.20 164.0 68.47 828 NA NA 4.1 3.06
252 39.3 10.90 131.2 41.73 876 NA NA 1.9 2.12
264 29.1 12.87 105.3 33.04 948 NA NA 4.1 1.98
276 20.1 8.77 74.7 24.81 1020 NA NA 2.0 2.21
288 22.5 5.94 78.3 21.99 1092 NA NA 0.9 1.66
300 20.0 5.20 91.6 29.83 1164 NA NA 1.5 2.11
312 12.6 4.34 88.9 26.16 1284 NA NA 1.2 1.71
324 11.7 3.66 85.2 28.94 1380 NA NA 0.5 1.40
336 28.5 18.61 68.4 16.72 1452 NA NA 0.0 0.00
348 12.9 5.94 52.5 26.43 1524 NA NA 0.0 0.00
Time time after the first injection (h), Plasma average concentration of tulathromycin in the plasma (ng/mL), Milk average concentration of CP-60,300 in the milk
(ng/mL), SD standard deviation, NA not applicable as no sample was taken
Table 3 Pharmacokinetic model parameters for plasma tulathromycin and milk CP-60,300 concentrations in lactating goats
Parameter Description Population
mean
IIV Bootstrap
value
2.5% CI 97.5% CI
V (mL) Volume of distribution for the central compartment 326627 1.072 260011.65 169213.19 369548.19
Cl (mL/h) Central clearance 21109.2 0.184 19214.724 16224.881 22463.998
V2 (mL) Volume of distribution for the peripheral compartment 676758 0.232 721665.92 567400.38 835445.28
Cl2 (mL/h) Clearance between the central and the peripheral compartment 12550.5 0.710 16958.522 11499.469 24340.243
CLmilk (mL/h) Clearance from the central compartment to the milk 882.461 0.121 816.285 686.264 957.191
Ka (1/h) Absorption rate constant after subcutaneous (SC) injection 0.295 6.255 0.938 0.327 2.318
Residue error 1 (%) Proportional error model of tulathromycin concentrations
in plasma
0.485 NA 0.484 0.419 0.549
Residue error 2 (%) Proportional error model of CP-60,300 cumulative amounts in milk 0.0234 NA 0.0228 0.0157 0.0279
CI confidence interval, IIV interindividual variability, NA not available
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Model simulations
The simulated time-concentration (or amount) profiles
of tulathromycin in plasma and the marker residue CP-
60,300 in milk from the final pharmacokinetic model are
shown in Fig. 5. Based on the time-concentration pro-
files and LOD in plasma, it was estimated with a 95%
confidence that the plasma concentration was below
LOD 43 days after a single SC injection, and 62 days after
the second injection in a 2-injection regimen (7-day inter-
val) (Fig. 5a, b).
The simulated time-cumulative amounts of CP-60,300
in milk displayed a hyperbolic increase at the early phase
after injection, started to reach a plateau on ~25 days after
the first injection, and continuously increased slowly even
up to the last simulation time points, which were day 64
after the single injection (Fig. 5c, d). The simulated time-
concentration profiles in milk fluctuated throughout the
simulation period (Fig. 5e, f). However, the overall trend of
decreasing in the concentrations of CP-60,300 in milk after
injection was still observed and the simulated concentra-
tions matched well with the measured concentrations. The
fluctuating milk concentrations at the terminal kinetic
phase prevented from estimating milk withdrawal time for
tulathromycin in goats. Therefore, a definite conclusion on
the milk withdrawal time recommendation cannot be
made from this study. Nevertheless, based on the experi-
mental data of CP-60,300 in milk, concentrations of the
marker residue above the LOD were not measured in the
milk beyond 45 days after the single injection [12], and
39 days after the second injection in the 2-injection regi-
men (7-day interval) for the present studied population of
animals.
Discussion
This study reports plasma and milk pharmacokinetic
data up to 2 months after twice SC injections of 2.5 mg/
kg tulathromycin with a 7-day interval in lactating goats.
There were palpable injection-site reactions, but no sub-
stantial adverse clinical signs occurred; the body weight
and milk production were not affected negatively. These
observations suggest that twice SC injections of 2.5 mg/
kg tulathromycin do not cause clinical adverse reactions
in lactating goats, and could be considered for treating
lung infections in lactating goats provided that extra-
label drug use requirements are met.
Based on the new data in this study and previously
published single SC injection pharmacokinetic data in
goats [3, 12], a NLME-PK model for tulathromycin in
Fig. 3 Goodness-of-fit plots of plasma tulathromycin concentrations and milk cumulative excreted amounts of tulathromycin marker residue
CP-60,300 in lactating goats. Comparisons between observed versus individual predicted tulathromycin concentrations or CP-60,300 amounts in
the plasma (a) and milk (b), respectively
Fig. 4 Comparisons of observed versus individual predicted time-concentration profiles in plasma (a) and time-cumulative excreted amount
profiles in milk (b) of lactating goats. Unfilled circles represent experimentally observed data from Clothier et al. [3], Grismer et al. [12], and the
present pharmacokinetic study. Dotted lines represent model simulation results
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lactating goats was created. The model-predicted plasma
concentration and milk cumulative excreted amount
data correlated well with the experimental data (Figs. 3
and 4). The model is an excellent tool to estimate tula-
thromycin plasma and milk depletion profiles (Fig. 5).
However, one limitation is that the model can only pre-
dict the cumulative excreted amounts in milk and the
milk concentrations of tulathromycin marker residue have
to be calculated by dividing the measured volumes of milk
samples, which were different between different milking
periods (range 7–14 lbs/day). This was one of the reasons
why the model-predicted milk concentrations of tulathro-
mycin marker residue exhibited a fluctuating pattern at
the terminal phase, which was consistent with the mea-
sured data (Table 2).
The model predicted that a very long period (62 days)
would be needed to ensure that plasma concentrations of
tulathromycin and milk concentrations of the marker resi-
due fell below the LOD in 95% of the population following
two administrations of tulathromycin 7 days apart. One of
the reasons for this is that the model was built using time-
concentration data from several studies with variable
characteristics such as age, body weight, and milk produc-
tion. Unfortunately, data for these factors were not reported
for all the studies, so explanatory co-variates for the pharma-
cokinetic variability could not be included in the final model.
The pharmacokinetic parameters’ variability therefore repre-
sents the variability across all the included studies and, as a
result, the model predicted a wide range of concentrations
to encompass the full 95% of the study population.
Note that the milk concentration analysis was based
on the marker residue CP-60,300, which is a common
fragment of both the parent compound and metabolites
of tulathromycin. In contrast, only the parent tulathro-
mycin was measured in the plasma. This is a limitation
of the current study, since it is based on the assumption
that the ratio between parent drug concentrations in the
plasma and total residues in the milk is constant. How-
ever, this approach to the analysis may be a contributing
factor to the fluctuating milk concentrations that were
observed in the study (i.e., the milk concentration may
represent mainly the parent drug at the early kinetic
phase and then primarily the metabolites at the later
phase). To further optimize the present model, additional
Fig. 5 Simulated data for the plasma tulathromycin concentrations (a, b), cumulative excreted amounts of marker residue CP-60,300 in milk (c, d),
milk concentrations (e, f) of CP-60,300 in lactating goats after single or twice injections. The solid and dashed black lines represent the 95th and
50th percentiles of the simulated data, respectively. The solid and dotted red lines represent limit of detection (LOD) and limit of quantification
(LOQ), respectively, in milk (LOD = 1.8 ng/mL, LOQ = 5 ng/ml) and plasma (LOD = 1.2 ng/mL, LOQ = 4 ng/ml). The empty purple circles represent
the measured data from Grismer et al. [12] and the present pharmacokinetic study
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studies using more sensitive and specific analytical method
are needed to determine milk concentrations of both tula-
thromycin and the marker residue CP-60,300. In addition,
high milk:plasma partition coefficient (~10) and relatively
high protein bound percentage (~50%) of tulathromycin
in goats may contribute to the fluctuating milk concentra-
tions at the terminal phase [10, 12].
As introduced before, another helpful approach in the
estimation of withdrawal times is PBPK modeling, which
can be used to predict both the concentrations and the
cumulative excreted amounts of drugs in the milk [17, 18].
Therefore, future studies that extend the published tula-
thromycin PBPK model in juvenile and market-age meat
goats [10] to lactating goats are needed to compare the
estimated withdrawal intervals from different approaches
(NLME-PK vs. PBPK), and then to determine a more ac-
curate estimate to protect food safety.
The estimated times when plasma tulathromycin con-
centrations were below 1.2 ng/mL LOD were 43 days
after a single SC injection and 62 days after the second
injection in the 2-injection regimen. This estimation was
based on the LOD because the tolerance for tulathromy-
cin in goat milk is not available in the US or Europe.
Tulathromycin marker residue LOD in milk is much
lower than the tolerance of 5.5 ppm (5500 ng/ml) in cattle
liver (the target tissue). However, cattle liver tolerance is
not appropriate to be used to estimate milk withdrawal
time because milk is consumed on a regular basis and in
large quantities compared to cattle liver. Consequently, a
conservative estimate based on goat milk-specific data is
necessary in order to provide a precautionary withdrawal
time estimation.
Our previous study reported that a withdrawal interval
of at least 45 days are needed when tulathromycin is ad-
ministered to lactating goats SC at a dose of 2.5 mg/kg
[12]. However, plasma/milk sampling did not extend be-
yond 45 days after injection, nor was an NLME-PK
model developed to estimate the upper limit of the 95%
confidence intervals of plasma and milk concentrations.
The present study confirms the previous study finding
and further demonstrate that for twice SC administra-
tions of tulathromycin a withdrawal interval of 39 days
after the second injection (i.e., 46 days after the first in-
jection) is needed for milk concentrations to fall below
tolerance (i.e., LOD if official tolerance is not available)
for the studied population of animals. Additionally, our
NLME-PK model simulations showed that 62 days after
the second injection in the 2-injection regimen are
needed for plasma concentration to fall below the tolerance
for 95% of the simulated population. It should be noted
that the longer estimated time for plasma to fall below tol-
erance than the time for milk was because the former has
taken into account the population variability, whereas the
later was simply based on the present experiment using a
limited number of animals. Other laboratories have re-
ported lower LODs (0.46-0.7 ng/mL in plasma) using
more sensitive liquid chromatography tandem mass
spectrometry (LC-MS/MS) methods [8, 9, 19]. Based on
LOD of 0.7 ng/mL in plasma, the estimated time when
plasma concentrations fall below LOD will be >70 days
after the second injection in the 2-injection paradigm.
Conclusions
In summary, this study suggests that, although two SC
injections of 2.5 mg/kg tulathromycin is a safe treatment
for pulmonary infections in lactating goats, there is
considerable potential for contamination of the human
food supply unless a prolonged and extended withdrawal
interval is observed. The experimental data showed that
the marker residue CP-60,300 concentrations were below
LOD in all milk samples from the studied animals at
39 days after the second injection. However, a much lon-
ger withdrawal time of 62 days would be needed to ensure
tulathromycin concentrations in both plasma and milk fall
below the LOD in 95% of the population. These estimated
times are much longer than the current meat withdrawal
time recommendation of 18 days in non-lactating cattle
and of 5 days for swine. Therefore, tulathromycin use
in lactating goats should be cautious and an extended
withdrawal period should be considered. Nevertheless,
a definite milk withdrawal time recommendation for a
large diverse population of lactating goats cannot be made
due to the fluctuating milk concentration at the terminal
kinetic phase and milk samples should be tested before
milk is allowed to enter the human food chain. Additional
studies using more sensitive and specific analytical method
to determine milk concentrations of both tulathromycin
and the marker residue CP-60,300 and using Bayesian
population PBPK modeling approaches are needed to
provide a comparative, and potentially, more conservative
milk withdrawal time estimation.
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